Global Antiviral Drugs Market Overview
Global Antiviral Drugs Market was valued at USD 64.11 Billion in 2023 and is expected to reach USD 96.93 Billion by the year 2032, at a CAGR of 4.7%.
Antiviral drugs are a class of medication that is used to kill or suppress the ability of a virus to replicate hence it prohibits the virus potential to proliferate and reproduce. Viruses are made of genetic material such as DNA or RNA which is alive when it is outside in the environment but gains its ability to reproduce and proliferate when it enters a susceptible host. In addition, antiviral drugs can prevent and protect individuals from getting viral infections or spreading the virus to others. Moreover, the development of antivirals is the outcome of newly acquired knowledge of the molecular and genetic activity of organisms letting us better apprehend the structure and function of viruses, chief advances in the techniques for finding novel drugs, and the stress placed on the medical sector to deal with the human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome is propelling the market growth in the period of forecast.
According to Statista, the global antiviral drug market is anticipated to reach 75 billion US dollars in 2027 from 52 billion US dollars in 2019. Additionally, there are many viruses which to date don't have antiviral drugs to treat the cause such as Rabies and HIV. According to WHO, 37.7 million people were living with HIV in 2020. Furthermore, to provide relief from viral diseases antiviral drugs are used, they significantly reduce the symptoms hence helps the infected individual to feel better, these factors are promoting the growth of the antiviral drugs market throughout the forecast.
COVID-19 Impact on Antiviral Drugs Market
The COVID-19 outbreak has significantly increased the demand for antiviral drugs globally. Moreover, COVID-19 disease has instigated governments to increase funding for research and development of antiviral drugs. COVID-19 has spurred the demand for antiviral drugs. Moreover, COVID-19 is an infectious viral disease of the upper respiratory tract hence it has a positive impact on the antiviral drug market. Furthermore, a government-imposed ban on transportation and the number of workers presents in antiviral drug manufacturing companies caused a small yet considerable impact on the production and supply chain.
Market Dynamics And Factors of Antiviral Drugs Market
Drivers:
The advantages of antiviral drugs are that they can cure some viral illnesses like hepatitis C or decrease the course of other viral illnesses like influenza. Antiviral drugs can be used to prevent the outbreak of certain viral illnesses like herpes. Moreover, characteristics of anti-viral drugs such as they can enter the cell infected with the virus and interfere with viral nucleic acid synthesis and thus restrict the virus ability to reproduce and proliferate in number thus, strengthening the growth of the anti-viral drugs market in the period o forecast. Furthermore, there has been a significant rise in the number of viral disease outbreaks in recent times hence to reduce future outbreaks there is a need for antiviral drugs hence strengthening the expansion of the antiviral drug market throughout the forecast.
Viral disease like smallpox is no longer a threat to the human population due to global vaccination programs. Furthermore, Polio caused by poliovirus is on the verge of extinction due to the wide-scale of antiviral drugs incorporated to prevent poliovirus from infecting healthy individuals. All these notable factors are promoting the use of antiviral drugs to prevent and eradicate viral diseases. Moreover, the increasing number of HIV, herpes, influenza, and other viral infections are driving the antiviral drug market. Furthermore, an increase in research and development activities for generating novel and advance formulations, such as vaccines, broad-spectrum antiviral drugs, and combination therapies to treat viral infection is propelling the antiviral drugs market.
Restraints:
Modern science technology has reached record height due to the research and development going on in this sector since the mid-20th century. Despite the rigorous research to find antivirals the arsenal of antivirals drugs remains dangerously small. Additionally, only about 100 antiviral drugs are available in the US market. Moreover, the lack of rapid diagnostic tests to identify viruses is hampering the antiviral drugs market in the period of forecast. Furthermore, the safety of antiviral drugs is a matter of concern. Moreover, a tremendous amount of money is utilized for manufacturing drugs which results in high pricing of antiviral drugs hence restraining the growth of the antiviral drugs market during the period of forecast. Antiviral drug resistance is a growing concern in immunocompromised individual populations, where ongoing viral replication and prolonged drug exposure results in the development of resistant strains. Moreover, WHO has reported cases of resistance to most antivirals including antiretroviral (ARV) drugs which are used to treat HIV thus hindering the antiviral drug market development in the span of the forecast. Furthermore, the growing trend of alternative medicines such as naturopathy and homeopathy are restraining the growth of the antiviral drug market throughout the forecast period.
Challenges:
To test the safety and efficiency of antiviral drugs, they are given to healthy individuals, however, sometimes it can cause adverse life-threatening situations thus trials on healthy individuals are the major challenge for the antiviral drug manufacturer. Moreover, urbanization has resulted in zoonosis (transfer of diseases from animals to humans) which has affected several economies worldwide. Furthermore, analyzing the disease-causing viral organism and producing antiviral drugs against it within a short period is one of the vital challenges for market players. In addition, on average to develop a novel antiviral drug takes around 10 to 15 years thus to reduce the time involved in research and developing effective antiviral drugs in a limited period is the biggest challenge for market players involved in antiviral drug manufacturing.
Opportunities:
The increasing number of viral infections and the growing demand for antiviral drugs is the major opportunity for market players. Moreover, several governments are investing huge funds in research and development to provide antiviral drugs to their population hence providing ample opportunities for market players. Developing broad-spectrum antiviral drugs with promising effects is a vital opportunity for market players.
Market Segmentation
Segmentation Analysis of Antiviral Drugs Market:
Based on Drug Action Mechanisms, Reverse Transcriptase Inhibitors are anticipated to have the highest share in the antiviral drugs market. The increasing number of HIV patients globally and the efficiency of these medicines to treat HIV infection are the key factors promoting the use of Reverse Transcriptase Inhibitors. Protease inhibitors are expected to have the second-highest share in the antiviral drug market owing to their ability to block the spread of HIV to uninfected cells.
Based on Application, the HIV segment is expected to dominate the antiviral drug market owing to the increasing cases of HIV patients. HIV followed by Hepatitis is estimated to have the second-largest share in the antiviral drug market owing to vaccination against Hepatitis A and Hepatitis B.
Based on Type, the antiviral drug market is segmented into branded and generic. The branded segment is estimated to dominate the antiviral drug market throughout the forecast owing to priorities given to branded drugs considering their effectiveness and almost negligible side effects. The generic segment is also expected to have significant growth in developing and underdeveloped countries owing to low prices and having almost the same efficacy as branded medicines.
Based on Age Group, the Geriatric segment is anticipated to lead the market owing to the increasing geriatric population and the high risk associated to contract the virus.
Regional analysis of Antiviral Drugs Market:
Depending on geography, the antiviral drug market is segmented into 5 regions North America, Middle East, and Africa, Asia-Pacific, Europe, and South America.
North America is anticipated to dominate the antiviral drug market in the period of forecast owing to the enhanced and well-developed healthcare sector. Furthermore, the U.S. government is undertaking several measures including investment in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.
Asia-Pacific region is expected to grow at the fastest growth rate owing to the increasing prevalence and treatment rate of viral infections, developing healthcare sector, increasing number of research institutes, and increasing health awareness among people about infectious diseases.
Europe region is estimated to have a positive growth rate in the period of forecast. The well-developed healthcare sector, presence of major research institutes is propelling the antiviral drug market in this region.
Players Covered in Antiviral Drugs Market are:
- Gilead Sciences Inc (US)
- GlaxoSmithKline plc (UK)
- Johnson & Johnson Services Inc (US)
- AstraZeneca (UK)
- AbbVie Inc (US)
- Merck & Co Inc (US)
- Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US)
- Bristol-Myers Squibb Company (US)
- Zydus Cadila (India)
- Cipla Inc (India)
- Prinston Pharmaceutical Inc (US)
- Hetero (India)
- Aurobindo Pharma (India)
- Apotex Inc (Canada)
- Mylan N.V. (US)
- Vir Biotechnology Inc (US) and others major key players.
Key Industry Development in Antiviral Drugs Market
- In September 2024, Hyundai Bioscience announced XAFTY®, a broad-spectrum antiviral effective against COVID-19, mpox, dengue, and H1N1, at the "Disease Prevention and Control Summit 2024." Currently in Phase 3 trials, XAFTY® aims to transform the antiviral drug market with its multi-target approach and advanced delivery technology.
- In April 2024, Onconova Therapeutics and Trawsfynydd Therapeutics announced a merger to form Traws Pharma, focusing on developing best-in-class antivirals. The combined company, with $28 million in funding from a private placement led by OrbiMed and Torrey Pines, will advance its antiviral assets, including viroksavir for influenza, travaltrelvir for COVID-19, and narazaciclib for endometrial cancer. With multiple clinical data catalysts expected in 2024, Traws Pharma aims to be a key player in the antiviral drug market.
Global Antiviral Drugs Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 64.11 Bn. |
Forecast Period 2024-32 CAGR: |
4.7% |
Market Size in 2032: |
USD 96.93 Bn. |
Segments Covered: |
By Type |
|
|
By Application |
|
||
By Age Group |
|
||
By Mechanism of Action |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
3.3 By Age Group
3.4 By Mechanism of Action
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Antiviral Drugs Market by Type
5.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
5.2 Antiviral Drugs Market Overview
5.3 Branded
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Branded: Grographic Segmentation
5.4 Generics
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Generics: Grographic Segmentation
Chapter 6: Antiviral Drugs Market by Application
6.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
6.2 Antiviral Drugs Market Overview
6.3 Influenza
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Influenza: Grographic Segmentation
6.4 HIV
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 HIV: Grographic Segmentation
6.5 Hepatitis
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Hepatitis: Grographic Segmentation
6.6 Herpes Simplex Virus {HSV}
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Herpes Simplex Virus {HSV}: Grographic Segmentation
6.7 Coronavirus Infection
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Coronavirus Infection: Grographic Segmentation
6.8 Human Papillomavirus
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2017-2032F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Human Papillomavirus: Grographic Segmentation
6.9 Others
6.9.1 Introduction and Market Overview
6.9.2 Historic and Forecasted Market Size (2017-2032F)
6.9.3 Key Market Trends, Growth Factors and Opportunities
6.9.4 Others: Grographic Segmentation
Chapter 7: Antiviral Drugs Market by Age Group
7.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
7.2 Antiviral Drugs Market Overview
7.3 Adult
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Adult: Grographic Segmentation
7.4 Pediatric
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Pediatric: Grographic Segmentation
Chapter 8: Antiviral Drugs Market by Mechanism of Action
8.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
8.2 Antiviral Drugs Market Overview
8.3 DNA Polymerase Inhibitors
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size (2017-2032F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 DNA Polymerase Inhibitors: Grographic Segmentation
8.4 Reverse Transcriptase Inhibitors
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size (2017-2032F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Reverse Transcriptase Inhibitors: Grographic Segmentation
8.5 Protease Inhibitors
8.5.1 Introduction and Market Overview
8.5.2 Historic and Forecasted Market Size (2017-2032F)
8.5.3 Key Market Trends, Growth Factors and Opportunities
8.5.4 Protease Inhibitors: Grographic Segmentation
8.6 Neuraminidase Inhibitors
8.6.1 Introduction and Market Overview
8.6.2 Historic and Forecasted Market Size (2017-2032F)
8.6.3 Key Market Trends, Growth Factors and Opportunities
8.6.4 Neuraminidase Inhibitors: Grographic Segmentation
8.7 Integrase inhibitors
8.7.1 Introduction and Market Overview
8.7.2 Historic and Forecasted Market Size (2017-2032F)
8.7.3 Key Market Trends, Growth Factors and Opportunities
8.7.4 Integrase inhibitors: Grographic Segmentation
8.8 Attachment inhibitors
8.8.1 Introduction and Market Overview
8.8.2 Historic and Forecasted Market Size (2017-2032F)
8.8.3 Key Market Trends, Growth Factors and Opportunities
8.8.4 Attachment inhibitors: Grographic Segmentation
8.9 Others
8.9.1 Introduction and Market Overview
8.9.2 Historic and Forecasted Market Size (2017-2032F)
8.9.3 Key Market Trends, Growth Factors and Opportunities
8.9.4 Others: Grographic Segmentation
Chapter 9: Company Profiles and Competitive Analysis
9.1 Competitive Landscape
9.1.1 Competitive Positioning
9.1.2 Antiviral Drugs Sales and Market Share By Players
9.1.3 Industry BCG Matrix
9.1.4 Ansoff Matrix
9.1.5 Antiviral Drugs Industry Concentration Ratio (CR5 and HHI)
9.1.6 Top 5 Antiviral Drugs Players Market Share
9.1.7 Mergers and Acquisitions
9.1.8 Business Strategies By Top Players
9.2 GILEAD SCIENCES INC
9.2.1 Company Overview
9.2.2 Key Executives
9.2.3 Company Snapshot
9.2.4 Operating Business Segments
9.2.5 Product Portfolio
9.2.6 Business Performance
9.2.7 Key Strategic Moves and Recent Developments
9.2.8 SWOT Analysis
9.3 GLAXOSMITHKLINE PLC
9.4 JOHNSON & JOHNSON SERVICES INC
9.5 ASTRAZENECA
9.6 ABBVIE INC
9.7 MERCK & CO INC
9.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
9.9 REGENERON PHARMACEUTICALS INC
9.10 BRISTOL-MYERS SQUIBB COMPANY
9.11 ZYDUS CADILA
9.12 CIPLA INC
9.13 PRINSTON PHARMACEUTICAL INC
9.14 HETERO
9.15 AUROBINDO PHARMA
9.16 APOTEX INC
9.17 MYLAN N.V.
9.18 VIR BIOTECHNOLOGY INC.
9.19 OTHER MAJOR PLAYERS
Chapter 10: Global Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Market Overview
10.2 Historic and Forecasted Market Size By Type
10.2.1 Branded
10.2.2 Generics
10.3 Historic and Forecasted Market Size By Application
10.3.1 Influenza
10.3.2 HIV
10.3.3 Hepatitis
10.3.4 Herpes Simplex Virus {HSV}
10.3.5 Coronavirus Infection
10.3.6 Human Papillomavirus
10.3.7 Others
10.4 Historic and Forecasted Market Size By Age Group
10.4.1 Adult
10.4.2 Pediatric
10.5 Historic and Forecasted Market Size By Mechanism of Action
10.5.1 DNA Polymerase Inhibitors
10.5.2 Reverse Transcriptase Inhibitors
10.5.3 Protease Inhibitors
10.5.4 Neuraminidase Inhibitors
10.5.5 Integrase inhibitors
10.5.6 Attachment inhibitors
10.5.7 Others
Chapter 11: North America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Branded
11.4.2 Generics
11.5 Historic and Forecasted Market Size By Application
11.5.1 Influenza
11.5.2 HIV
11.5.3 Hepatitis
11.5.4 Herpes Simplex Virus {HSV}
11.5.5 Coronavirus Infection
11.5.6 Human Papillomavirus
11.5.7 Others
11.6 Historic and Forecasted Market Size By Age Group
11.6.1 Adult
11.6.2 Pediatric
11.7 Historic and Forecasted Market Size By Mechanism of Action
11.7.1 DNA Polymerase Inhibitors
11.7.2 Reverse Transcriptase Inhibitors
11.7.3 Protease Inhibitors
11.7.4 Neuraminidase Inhibitors
11.7.5 Integrase inhibitors
11.7.6 Attachment inhibitors
11.7.7 Others
11.8 Historic and Forecast Market Size by Country
11.8.1 U.S.
11.8.2 Canada
11.8.3 Mexico
Chapter 12: Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Branded
12.4.2 Generics
12.5 Historic and Forecasted Market Size By Application
12.5.1 Influenza
12.5.2 HIV
12.5.3 Hepatitis
12.5.4 Herpes Simplex Virus {HSV}
12.5.5 Coronavirus Infection
12.5.6 Human Papillomavirus
12.5.7 Others
12.6 Historic and Forecasted Market Size By Age Group
12.6.1 Adult
12.6.2 Pediatric
12.7 Historic and Forecasted Market Size By Mechanism of Action
12.7.1 DNA Polymerase Inhibitors
12.7.2 Reverse Transcriptase Inhibitors
12.7.3 Protease Inhibitors
12.7.4 Neuraminidase Inhibitors
12.7.5 Integrase inhibitors
12.7.6 Attachment inhibitors
12.7.7 Others
12.8 Historic and Forecast Market Size by Country
12.8.1 Germany
12.8.2 U.K.
12.8.3 France
12.8.4 Italy
12.8.5 Russia
12.8.6 Spain
12.8.7 Rest of Europe
Chapter 13: Asia-Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Branded
13.4.2 Generics
13.5 Historic and Forecasted Market Size By Application
13.5.1 Influenza
13.5.2 HIV
13.5.3 Hepatitis
13.5.4 Herpes Simplex Virus {HSV}
13.5.5 Coronavirus Infection
13.5.6 Human Papillomavirus
13.5.7 Others
13.6 Historic and Forecasted Market Size By Age Group
13.6.1 Adult
13.6.2 Pediatric
13.7 Historic and Forecasted Market Size By Mechanism of Action
13.7.1 DNA Polymerase Inhibitors
13.7.2 Reverse Transcriptase Inhibitors
13.7.3 Protease Inhibitors
13.7.4 Neuraminidase Inhibitors
13.7.5 Integrase inhibitors
13.7.6 Attachment inhibitors
13.7.7 Others
13.8 Historic and Forecast Market Size by Country
13.8.1 China
13.8.2 India
13.8.3 Japan
13.8.4 Singapore
13.8.5 Australia
13.8.6 New Zealand
13.8.7 Rest of APAC
Chapter 14: Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Branded
14.4.2 Generics
14.5 Historic and Forecasted Market Size By Application
14.5.1 Influenza
14.5.2 HIV
14.5.3 Hepatitis
14.5.4 Herpes Simplex Virus {HSV}
14.5.5 Coronavirus Infection
14.5.6 Human Papillomavirus
14.5.7 Others
14.6 Historic and Forecasted Market Size By Age Group
14.6.1 Adult
14.6.2 Pediatric
14.7 Historic and Forecasted Market Size By Mechanism of Action
14.7.1 DNA Polymerase Inhibitors
14.7.2 Reverse Transcriptase Inhibitors
14.7.3 Protease Inhibitors
14.7.4 Neuraminidase Inhibitors
14.7.5 Integrase inhibitors
14.7.6 Attachment inhibitors
14.7.7 Others
14.8 Historic and Forecast Market Size by Country
14.8.1 Turkey
14.8.2 Saudi Arabia
14.8.3 Iran
14.8.4 UAE
14.8.5 Africa
14.8.6 Rest of MEA
Chapter 15: South America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
15.1 Key Market Trends, Growth Factors and Opportunities
15.2 Impact of Covid-19
15.3 Key Players
15.4 Key Market Trends, Growth Factors and Opportunities
15.4 Historic and Forecasted Market Size By Type
15.4.1 Branded
15.4.2 Generics
15.5 Historic and Forecasted Market Size By Application
15.5.1 Influenza
15.5.2 HIV
15.5.3 Hepatitis
15.5.4 Herpes Simplex Virus {HSV}
15.5.5 Coronavirus Infection
15.5.6 Human Papillomavirus
15.5.7 Others
15.6 Historic and Forecasted Market Size By Age Group
15.6.1 Adult
15.6.2 Pediatric
15.7 Historic and Forecasted Market Size By Mechanism of Action
15.7.1 DNA Polymerase Inhibitors
15.7.2 Reverse Transcriptase Inhibitors
15.7.3 Protease Inhibitors
15.7.4 Neuraminidase Inhibitors
15.7.5 Integrase inhibitors
15.7.6 Attachment inhibitors
15.7.7 Others
15.8 Historic and Forecast Market Size by Country
15.8.1 Brazil
15.8.2 Argentina
15.8.3 Rest of SA
Chapter 16 Investment Analysis
Chapter 17 Analyst Viewpoint and Conclusion
Global Antiviral Drugs Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 64.11 Bn. |
Forecast Period 2024-32 CAGR: |
4.7% |
Market Size in 2032: |
USD 96.93 Bn. |
Segments Covered: |
By Type |
|
|
By Application |
|
||
By Age Group |
|
||
By Mechanism of Action |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Antiviral Drugs Market research report is 2024-2032.
Gilead Sciences Inc (US), GlaxoSmithKline plc (UK), Johnson & Johnson Services Inc (US), AstraZeneca (UK), AbbVie Inc (US), Merck & Co Inc (US), Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US), Bristol-Myers Squibb Company (US), Zydus Cadila (India), Cipla Inc (India), Prinston Pharmaceutical Inc (US), Hetero (India), Aurobindo Pharma (India), Apotex Inc (Canada), Mylan N.V. (US), Vir Biotechnology Inc (US), and Other Major Players.
Antiviral Drugs Market is segmented into Type, Application, Age Group, Mechanism of Action and region. By Type, the market is categorized into Branded, Generics. By Application, the market is categorized into Influenza, HIV, Hepatitis, Coronavirus Infection, Human Papillomavirus, Others. By Age Group the market is categorized into Adult, Pediatric. By Mechanism of Action, the market is categorized into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Antiviral drugs are a class of medication that is used to kill or suppress the ability of a virus to replicate hence it prohibits the virus potential to proliferate and reproduce. Viruses are made of genetic material such as DNA or RNA which is alive when it is outside in the environment but gains its ability to reproduce and proliferate when it enters a susceptible host.
Global Antiviral Drugs Market was valued at USD 64.11 Billion in 2023 and is expected to reach USD 96.93 Billion by the year 2032, at a CAGR of 4.7%.